Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5755MR)

This product GTTS-WQ5755MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5755MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7984MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ10168MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ4681MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ12066MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ176MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ14617MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ8740MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ9089MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW